A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.

JAMA Network Open
Ge LiuQiPing Feng

Abstract

Observational studies suggest that statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, may be associated with beneficial effects in many noncardiovascular diseases. To construct a weighted HMG-CoA reductase (HMGCR) gene genetic risk score (GRS) using variants in the HMGCR gene affecting low-density lipoprotein cholesterol as an instrumental variable for mendelian randomization analyses to test associations with candidate noncardiovascular phenotypes previously associated with statin use in observational studies. This cohort study included 53 385 unrelated adults of European ancestry with genome-wide genotypes available from BioVU (a practice-based biobank, used for discovery) and 30 444 unrelated adults with European ancestry available in the Electronic Medical Records and Genomics (eMERGE; a research consortium that conducts genetic research using electronic medical records, used for replication). The study was conducted from February 6, 2015, through April 31, 2019; data analysis was performed from August 26, 2019, through December 22, 2020. An HMGCR GRS was calculated. The association between the HMGCR GRS and the presence or absence of 22 noncardiovascular phenotypes previously associated with ...Continue Reading

References

Nov 9, 2005·Neurology·C BernickUNKNOWN Cardiovascular Health Study Collaborative Research Group
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Aug 5, 2009·Journal of Neurology·Stella TrompetRudi G J Westendorp
Jan 13, 2010·Journal of the American Medical Informatics Association : JAMIA·Hua XuJoshua C Denny
Apr 7, 2010·American Journal of Human Genetics·Marylyn D RitchieDan M Roden
Jun 23, 2011·JAMA : the Journal of the American Medical Association·David PreissKausik K Ray
Apr 19, 2012·JAMA : the Journal of the American Medical Association·James S FloydBruce M Psaty
Jan 29, 2013·The American Journal of Cardiology·Eliano Pio NavareseJacek Kubica
Jun 8, 2013·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Omri GottesmanUNKNOWN eMERGE Network
Feb 3, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Xuemei HuangHonglei Chen
Jun 9, 2015·JAMA Internal Medicine·Brian L StromWarren B Bilker
Jan 9, 2016·The American Journal of Cardiology·Tushar AcharyaIshak A Mansi
Feb 26, 2016·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Xiaole SuHong Zhang
Dec 14, 2016·The New England Journal of Medicine·Brian A FerenceMarc S Sabatine
May 26, 2017·Journal of Human Genetics·QiPing FengC Michael Stein
Dec 21, 2018·Circulation·Jonathan D MosleyThomas J Wang
Jan 18, 2019·Circulation Research·Natalie C WardRobert H Eckel
Sep 12, 2019·JAMA Network Open·QiPing FengC Michael Stein

❮ Previous
Next ❯

Software Mentioned

eMERGE
PheCodes
BioVU
R Foundation for Statistical Computing
PheCode
R

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.